Previous studies searching for inhibitors in the atypical NFκB signaling pathways identified a specific inhibitor of androgen receptor and p52 interaction resulting in reduced levels of cyclin D1 expression used for the treatment of castration-resistant prostate cancer [45]. Here, NFKB1 is linked to prostate carcinoma.